GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genxone SA (WAR:GX1) » Definitions » EV-to-EBIT

Genxone (WAR:GX1) EV-to-EBIT : -3.84 (As of May. 29, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Genxone EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Genxone's Enterprise Value is zł14.35 Mil. Genxone's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was zł-3.74 Mil. Therefore, Genxone's EV-to-EBIT for today is -3.84.

The historical rank and industry rank for Genxone's EV-to-EBIT or its related term are showing as below:

WAR:GX1' s EV-to-EBIT Range Over the Past 10 Years
Min: -8.51   Med: 4.65   Max: 95.8
Current: -3.84

During the past 6 years, the highest EV-to-EBIT of Genxone was 95.80. The lowest was -8.51. And the median was 4.65.

WAR:GX1's EV-to-EBIT is ranked worse than
100% of 425 companies
in the Biotechnology industry
Industry Median: 9.85 vs WAR:GX1: -3.84

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Genxone's Enterprise Value for the quarter that ended in Mar. 2024 was zł13.56 Mil. Genxone's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was zł-3.74 Mil. Genxone's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -27.56%.


Genxone EV-to-EBIT Historical Data

The historical data trend for Genxone's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genxone EV-to-EBIT Chart

Genxone Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial - 7.28 5.21 35.40 -2.89

Genxone Quarterly Data
Mar19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.88 -6.30 -3.96 -2.89 -3.63

Competitive Comparison of Genxone's EV-to-EBIT

For the Biotechnology subindustry, Genxone's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genxone's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genxone's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Genxone's EV-to-EBIT falls into.



Genxone EV-to-EBIT Calculation

Genxone's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=14.352/-3.737
=-3.84

Genxone's current Enterprise Value is zł14.35 Mil.
Genxone's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was zł-3.74 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genxone  (WAR:GX1) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Genxone's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 ) =EBIT / Enterprise Value (Q: Mar. 2024 )
=-3.737/13.560396
=-27.56 %

Genxone's Enterprise Value for the quarter that ended in Mar. 2024 was zł13.56 Mil.
Genxone's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was zł-3.74 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genxone EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Genxone's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Genxone (WAR:GX1) Business Description

Traded in Other Exchanges
N/A
Address
ul. Kobaltowa 6, Zlotniki, Suchy Las, POL, 62-002
Genxone SA is a biotechnology company that applies nanopore sequencing technology (third-generation of NGS) to many areas of science and business, including genetic diagnostics and the food industry. It specializes in developing new products and solutions based on the latest technologies of nucleic acid sequencing. The company's services include NANOPORE SEQUENCING that includes Whole Genome Sequencing, Bespoke Analysis, Metagenome Sequencing, Bioinformatic Analysis, 16S and/or ITS Gene Sequencing, and RNA Sequencing; and DIAGNOSTIC TESTS that includes Gastrointestinal Infections Panel, Respiratory Infections Panel, Urogenital Infection Panel, and Nervous System Infection Panel.

Genxone (WAR:GX1) Headlines

No Headlines